A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia

Trial Profile

A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2017

At a glance

  • Drugs IONIS ANGPTL3Rx (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results published in the New England Journal of Medicine.
    • 15 Nov 2016 According to an Ionis Pharmaceuticals media release, results of interim analysis from the study were presented at the American Heart Association Scientific Sessions.
    • 15 Nov 2016 Interim results published in an Ionis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top